Tuuli Nissinen

Contact search available for JYU staff members.

ORCID link: https://orcid.org/0000-0003-1763-6083

Active JYU affiliations

Faculty of Sport and Health Sciences, Postdoctoral Researcher

Previous, inactive or other affiliations

Faculty of Sport and Health Sciences (University of Jyväskylä), Doctoral Student (employment relationship), Ended

Research interests

I study the effects and mechanisms of muscle wasting and the importance of maintaining muscle mass and quality in conditions that induce wasting. My research increases understanding of muscle physiology in different wasting conditions and results can be applied to prevention and treatment of muscle wasting.

Publications and other outputs

Muscle follistatin gene delivery increases muscle protein synthesis independent of periodical physical inactivity and fasting (2021) Nissinen, Tuuli A.; et al.; A1; OA
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments (2021) Hulmi, Juha J.; et al.; A2; OA
Molecular and physiological effects of muscle wasting and its treatment by blocking myostatin and activins (2020) Nissinen, Tuuli; G5; OA; 978-951-39-8468-7
Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia : the effects of blocking myostatin and activins (2020) Hulmi, J.; et al.; A1; OA
Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver (2019) Hentilä, Jaakko; et al.; A1; OA
Blocking Activin Receptor Ligands Is Not Sufficient to Rescue Cancer-Associated Gut Microbiota : A Role for Gut Microbial Flagellin in Colorectal Cancer and Cachexia? (2019) Pekkala, Satu; et al.; A1; OA
Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade (2019) Lautaoja, Juulia; et al.; A1; OA
Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle (2018) Hulmi, Juha; et al.; A1; OA
Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses (2018) Nissinen, Tuuli; et al.; A1; OA
Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes (2016) Nissinen, Tuuli; et al.; A1; OA
VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection (2016) Räsänen, Markus; et al.; A1